Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab With or Without Fianlimab in Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
NCT06205836Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jun 2024
- Primary completion
- May 2030
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab, fianlimab in colorectal cancer (CRC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jun 2024; status: recruiting.
02
Drugs
cemiplimabfianlimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06205836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205836.